News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Van Leeuwenhoeck Research Publishes Updated BioDiem Ltd. (BDM.AX) Analyst Report


4/5/2013 10:22:11 AM

Melbourne, 5 April 2013: Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX:BDM) has today announced the availability of an updated analyst report on the Company prepared by leading biotech and financial analyst company Van Leeuwenhoeck Research (VLR).

The research report provides a comprehensive overview of BioDiem’s key milestones and financial results since the previous Van Leeuwenhoeck Research report published last year (February 2012).

Key highlights include:

• BioDiem’s renewed corporate strategy, which was approved by the Board in April 2012, and which has seen the Company direct its focus on becoming a leading global vaccine and therapy company targeting infectious diseases.

• BioDiem’s partnerships with the vaccine companies, Serum Institute of India (SII) and Changchun BCHT Biotechnology for commercialisation of its proprietary Live Attenuated Influenza Virus (LAIV) technology:

-- SII intends to apply to the W.H.O. for permission to export its ‘flu vaccines using BioDiem’s LAIV technology in 2013 – increased sales of the vaccine in private markets would result in increased royalties for BioDiem; and

-- BCHT is building a new vaccine facility for manufacture of LAIV-based vaccines for the private Chinese market.

• BioDiem’s focus to grow a diverse vaccine business targeting infectious diseases which need effective treatments.

-- BioDiem successfully collaborated with French-based VIVALIS to test the production of LAIV in VIVALIS’ cell line over the last year.

• Significant progress in development of BioDiem’s antimicrobial compound, BDM-I, for commercialisation including:

-- Additional patents granted in the US, Japan and China;

-- A renewed contract with National Institutes of Health (NIH) to test BDM-I’s activity against a range of infectious fungi and tuberculosis; and

-- Extension of BioDiem’s research contract with the US Army Medical Research Institute for the testing of BDM-I against biological warfare agents.

• BioDiem’s cash position of AUD$2.3 million with revenues in 2011/12 of AUD$1.3 million predominantly from licensing revenues.

• Significant milestones expected in the next 12 months:

-- Royalty generating licenses for its proprietary LAIV influenza vaccine technology;

-- Potential commercial partnership for the therapeutic hepatitis vaccine platform;

-- Sale of BDM-E; and

-- Results of preclinical proof-of-concept studies of the BDM-I antimicrobial compound.

For more information or to view the research report, please visit www.biodiem.com

About BioDiem Ltd

BioDiem (ASX: BDM) is an ASX-listed company based in Melbourne with an international focus on discovering, developing and commercialising world-class research and technology targeting infectious diseases and related cancers. BioDiem’s core technologies include the Live Attenuated Influenza Virus (LAIV), the BDM-I antimicrobial compound and the SAVINE vaccine technology platform. BioDiem has also in-licensed vaccine technologies from Australian National University and the University of Canberra with initial target indications of dengue fever and hepatitis respectively.

The LAIV influenza vaccine is an intranasal vaccine to prevent infection from seasonal and pandemic influenza. The LAIV influenza vaccine can be produced using both egg-based and cell-based manufacturing methods. BioDiem’s egg-based LAIV vaccine technology is licensed to the World Health Organization as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply in developing countries. The cell-based LAIV vaccine technology has completed a Phase II clinical trial in Europe in seasonal influenza. Serum Institute of India markets the influenza vaccine, Nasovac™ in India under a license from BioDiem. A licence has also been issued by BioDiem to China- based Changchun BCHT Biotechnology Co.

BDM-I is a synthetic compound targeting the treatment of serious human infections. BDM-I is in the preclinical stage with outlicensing as the intended outcome. BDM-I is active against a range of pathogenic micro-organisms including gram-positive and gram-negative bacteria, fungi and protozoa. Key patents have been granted in Europe, Japan and the US around BDM-I’s antimicrobial activity.

SAVINE (patented Scrambled Antigen Vaccine) is a platform technology for the design of antigens for incorporation into vaccines targeting a range of different diseases. SAVINE antigens, when partnered with technology such as BioDiem's LAIV-based vaccine vector technology, can be used to develop novel vaccines.

BioDiem’s research is ongoing in partnerships with internationally recognised laboratories and commercial groups.

For additional information, please visit www.biodiem.com

Contact

Investors

Julie Phillips, Chief Executive Officer

BioDiem Ltd

Phone +61 3 9613 4100

Email jphillips@biodiem.com

Media

Shevaun Cooper

Buchan Consulting

Phone +61 3 8866 1218 / +61 (0) 421 760 775

Email scooper@buchanwe.com.au


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES